Mercaptamine ophthalmic - Leadiant Biosciences

Drug Profile

Mercaptamine ophthalmic - Leadiant Biosciences

Alternative Names: Cystaran; Cysteamine; Cysteamine HCl; Cysteamine hydrochloride; Cysteamine ophthalmic solution; Dropcys

Latest Information Update: 06 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sigma-Tau Pharmaceuticals
  • Developer Leadiant Biosciences; Lucane Pharma
  • Class Antibacterials; Antidotes; Hepatoprotectants; Mercaptoethylamines; Mucolytics; Small molecules
  • Mechanism of Action Glutathione synthase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystinosis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cystinosis

Most Recent Events

  • 28 Feb 2017 Sigma-Tau Pharmaceuticals is now called Leadiant Biosciences
  • 01 Apr 2016 The Committee for Medicinal Products for Human Use (CHMP) recommends refusal of marketing authorisation for mercaptamine in European Union
  • 17 Dec 2015 Preregistration for Cystinosis in European Union before December 2015 (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top